Sensitivity of NS3 Serine Proteases from Hepatitis C Virus Genotypes 2 and 3 to the Inhibitor BILN 2061

Diane Thibeault,* Christiane Bousquet, Rock Gingras, Lisette Lagacé, Roger Maurice, Peter W. White, and Daniel Lamarre†

Department of Biological Sciences, Boehringer Ingelheim (Canada) Ltd., Research and Development, Laval, Quebec H7S 2G5, Canada

Received 3 February 2004/Accepted 12 March 2004

Hepatitis C virus (HCV) displays a high degree of genetic variability. Six genotypes and more than 50 subtypes have been identified to date. In this report, kinetic profiles were determined for NS3 proteases of genotypes 1a, 1b, 2a, 2b, and 3a, revealing no major differences in activity. In vitro sensitivity studies with BILN 2061 showed a decrease in affinity for proteases of genotypes 2 and 3 ($K_i$, 80 to 90 nM) compared to genotype 1 enzymes ($K_i$, 1.5 nM). To understand the reduced sensitivity of genotypes 2 and 3 to BILN 2061, active-site residues in the proximity of the inhibitor binding site were replaced in the genotype-1b enzyme with the corresponding genotype-2b or -3a residues. The replacement of five residues at positions 78, 79, 80, 122, and 132 accounted for most of the reduced sensitivity of genotype 2b, while replacement of residue 168 alone could account for the reduced sensitivity of genotype 3a. BILN 2061 remains a potent inhibitor of these non-genotype-1 NS3–NS4A proteins, with $K_i$ values below 100 nM. This in vitro potency, in conjunction with the good pharmacokinetic data reported for humans, suggests that there is potential for BILN 2061 as an antiviral agent for individuals infected with non-genotype-1 HCV.

According to the latest World Health Organization estimates, more than 170 million individuals may be infected with hepatitis C virus (HCV). Chronic infection, observed in about 85% of cases, could lead to progressive hepatic fibrosis, cirrhosis, and hepatocellular carcinoma (7). HCV belongs to the Flaviviridae family. Its positive-strand RNA genome contains 9,600 nucleotides and encodes a ~3,100-amino-acid protein that is posttranslationally processed by host- and virally encoded proteases into structural (C, E1, E2, p7) and nonstructural (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) proteins (23). The nonstructural (NS) proteins include enzymes necessary for protein maturation (NS2/3 and NS3 proteases) and viral replication (NS3 helicase/nucleoside triphosphatase and NS5B RNA polymerase).

The high rate of viral production linked to the low fidelity of the RNA polymerases (5, 6) leads to genetic heterogeneity of HCV in infected patients (20). Natural variants of HCV are currently classified into 6 genotypes and more than 50 subtypes (25). The genotypes differ by as much as 34% in their nucleotide sequences, resulting in approximately 30% amino acid sequence divergence between the encoded polyproteins, while subtypes can differ by as much as 23% of their nucleotide sequence. The degree of sequence variability also varies for the different subgenomic regions. For example, the core and the 3′ and 5′ nontranslated regions are more conserved, whereas the envelope region displays more variability (24, 31). Sequences coding for the NS3 protease domain and the NS5B polymerase show degrees of variability comparable to that for the complete genome.

The HCV infections most frequently encountered are caused by genotypes 1, 2, and 3 (18). In Europe, Japan, and the United States, more than 70% of the HCV-positive population is infected with genotype 1 (18, 31). The spread of genotype 1b is slowing in Western countries, and genotypes 1a and 3a, mainly transmitted by infected intravenous drug users, constitute the main source of new infections (22, 31). No significant differences in the severity of illness are associated with the HCV genotype (7). However, the genotype is the major determinant of the outcome of therapy. Indeed, many HCV genotype-1 patients are refractory to interferon-based therapy, and only about 50% of patients treated with pegylated interferon and ribavirin for 48 weeks achieve a sustained virological response. On the other hand, about 80% of patients infected with HCV genotypes 2 and 3 achieve a sustained virological response with this treatment (4).

The higher prevalence and lower rate of response to treatment associated with HCV genotype 1 infections prompted us to focus our drug discovery efforts primarily on enzymes from this genotype. We targeted the serine protease activity responsible for viral maturation (26), which has been shown to be essential for HCV replication in vivo (11). Inhibitors of the HCV serine protease were designed through a substrate-based approach (15–17) which led to the discovery of the macrocyclic tripeptide inhibitor BILN 2061 (12). BILN 2061 is a potent and competitive inhibitor of the NS3 proteases of genotypes 1a and 1b, with inhibition constant ($K_i$) values in the low nanomolar range. Its administration to genotype-1-infected patients for 2 days resulted in an impressive reduction in HCV RNA plasma levels and established the first proof of concept in humans for an HCV NS3 protease inhibitor [H. Hinrichsen, Y. Benhamou,

In this study, different natural variants of HCV NS3 protease are evaluated with regard to their kinetic properties and their sensitivity to BILN 2061. The full-length heterodimeric NS3–NS4A proteins of genotypes 2 and 3 and their respective NS3 protease domains were expressed in Escherichia coli, purified, characterized, and compared to genotype-1 enzymes, which were used for inhibitor optimization leading to BILN 2061. Very similar values for the kinetic parameters $K_m$ and $k_{cat}$ were observed for the various NS3–NS4A enzymes, while the sensitivity of genotype-2 and -3 enzymes to BILN 2061 was reduced relative to that of genotype 1, although the $K_m$ was still in the low nanomolar range ($<100\,\text{nM}$). Finally, residues that are different in different genotypes and are located in close proximity to the inhibitor binding site were substituted in genotype 1, and the chimeric enzymes were evaluated for their sensitivity to BILN 2061. Our data provide some insights into residues playing a role in inhibitor binding and, more importantly, suggest the beneficial potential of therapy with BILN 2061 in HCV genotype-2 and -3-infected individuals.

MATERIALS AND METHODS

Genetic constructs. The previously described NS3–NS4A coding region of genotype 1b, with a 28-residue N-terminal sequence containing a hexahistidine tag and a tobacco etch virus protease cleavage site (21), was amplified by PCR and then subcloned into the pET11a bacterial expression vector (Novagen). For genotype-2 and -3 enzymes, HCV RNA was isolated from serum samples, obtained before BILN 2061 administration, of patients infected with HCV genotypes 2a, 2b, and 3a. The HCV genotype was determined by the INNO-LIPA HCV II test kit (Innogenetics, Ghent, Belgium). Viral RNA was extracted from 140 μl of serum by using a QIAamp viral RNA purification kit (QIAGEN). Isolated RNA was reverse transcribed into cDNA by using Superscript II (Gibco BRL) with HCV-specific primers corresponding to sequences located 3′ to the NS4A gene. The antisense primers for the HCV RNA were 5′-CTGATGAGTTTCCACATGTTGCTGCCAGAAA-3′ for genotype 2b, 5′-ATTGGAGGAAAGTGTCCTCGGAGCA-3′ for genotype 2a, and 5′-CACCAGATACTGTTCGATG-3′ for genotype 3a. The cDNAs were used as templates for PCR amplification of a fragment spanning the NS3 and NS4A genes. The NS3–NS4A fragment for genotypes 2 and 3 was amplified by using primers corresponding to the six N-terminal amino acids of NS3 and the seven C-terminal amino acids encoded by the NS4A gene, since these amino acid sequences are highly conserved between genotypes and subtypes. The following primers were used: for genotypes 2a, 5′-CTCGATACGCTCCCTCCACTGGTTATCCAGGAACTGGTCCTCGGAGCA-3′ for genotype 2a, and 5′-CACAAGATTTCCCATGTTTCGATG-3′ for genotype 3a. The cDNAs were used as templates for PCR amplification of a fragment spanning the NS3 and NS4A genes. The NS3–NS4A fragment for genotypes 2 and 3 was amplified by using primers corresponding to the six N-terminal amino acids of NS3 and the seven C-terminal amino acids encoded by the NS4A gene, since these amino acid sequences are highly conserved between genotypes and subtypes. The following primers were used: for genotype 2a, forward primer 5′-CTCGATACGCTCCCTCCACTGGTTATCCAGGAACTGGTCCTCGGAGCA-3′ and reverse primer 5′-CACGCAGTCAGGTCAGTCAACATTCCCTCATCAACATCAAGGC-3′; for genotype 2b, 5′-CTCGGGATCCCTCCACTGGTTATCCAGGAACTGGTCCTCGGAGCA-3′ and reverse primer 5′-GACGGCGCTTCGCGCATGACTCTTCCCCATTCTGTTGCGATG-3′.

Expression and purification of the NS3 protease domains from bacteria. The NS3 protease domains (amino acids 1 to 180) were expressed in E. coli BL21(DE3) (genotypes 2b and 3a) or BL21(DE3) pLysS (genotypes 1a, 1b, and 2a) cells (Novagen). Bacteria were grown at 37°C in CircleGrow medium (Q-BioGene) supplemented with 100 μg of ampicillin/ml and 34 μg of chloramphenicol/ml. At mid-log phase, the culture was cooled to 22°C, and protein expression was induced with 0.5 mM isopropyl-β-D-thiogalactoside for 4 h. Then cells were harvested by centrifugation and the cell paste was frozen at −80°C. The cell paste was resuspended in 5 ml of lysis buffer (50 mM NaPO4 [pH 7.5], 20% glycerol, 1 mM EDTA, 0.5% Triton X-100, 0.5 M NaCl) per g of cells. For the genotype-1a enzyme, the lysis buffer was 50 mM NaPO4 (pH 7.5)-40% glycerol-1 mM EDTA-0.5% Triton X-100. The suspension obtained was processed in a Dounce homogenizer, supplemented with 20 mM MgCl2 and 10 μg of DNase 1ml, and incubated for 30 min on ice. The suspension obtained from E. coli Rosetta(DE3) was processed in a Dounce homogenizer, supplemented with 20 mM MgCl2 and 10 μg of DNase 1ml, and incubated for 20 min on ice, while the suspension obtained from E. coli BL21(DE3) cells was homogenized by using a microfluidizer. Following a brief sonication, the extract was clarified by a 30-min centrifugation at 150,000×g. The supernatant was diluted twofold in 50 mM NaPO4 (pH 7.5)-0.5 M NaCl, and imidazole was added to a final concentration of 25 mM. Then the solution was applied to a Hi-Trap Ni2+-chelating column (Amersham Biosciences). The NS3–NS4A proteins were eluted in 50 mM NaPO4, pH 7.5)-0.5 M NaCl-10% glycerol-0.1% NP-40–5 mM imidazole by using a 5 to 50 mM imidazole gradient. The enzyme-enriched fractions were pooled, diluted fourfold in 50 mM NaPO4 (pH 7.5)-10% glycerol-0.05% n-dodecyl-β-D-maltoside, and applied to a poly(U)-Sepharose affinity column (Amersham Biosciences) previously equilibrated in 50 mM NaPO4 (pH 7.0)-10% glycerol-0.2 M NaCl-0.05% n-dodecyl-β-D-maltoside–10 mM β-mercaptoethanol. The enzyme was eluted in the same buffer containing 0.1% NP-40.

All of the enzymes were estimated to be more than 90% pure as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The purified enzymes were stored at −80°C. The final yield ranged from 60 to 600 μg per liter of culture; the highest yield was obtained for the genotype-2b protease.

Expression and purification of the NS3 protease domains from bacteria. The NS3 protease domains (amino acids 1 to 180) were expressed in E. coli BL21(DE3) (genotypes 2b and 3a) or BL21(DE3) pLysS (genotypes 1a, 1b, and 2a) cells (Novagen). Bacteria were grown at 37°C in CircleGrow medium supplemented with 30 μg of kanamycin/ml and 34 μg of chloramphenicol/ml. At mid-log phase, the culture was cooled to 22°C, and zinc acetate was added to a final concentration of 50 μM. Protein expression was induced with 1 mM isopropyl-β-D-thiogalactoside. Three hours postinduction, cells were harvested by centrifugation, and the cell paste was frozen at −80°C. The cell paste was resuspended in 5 ml of lysis buffer (25 mM NaPO4 [pH 7.5], 10% glycerol, 1 mM EDTA, 0.1% octyl-β-D-glucoside, 15 mM NaCl) per g of cells. For the NS3 protease of genotype 3a, the lysis buffer contained 25 mM MgCl2 and 10 μg of DNase I/ml, and incubated for 20 min on ice, while the suspension obtained from E. coli BL21(DE3) cells was homogenized by using a microfluidizer. Following a brief sonication, the extract was clarified by a 30-min centrifugation at 21,200×g. Then the purification was performed essentially as described previously (13). Briefly, the protease domains were separated from the soluble fraction by batch affinity chromatography on Superdex 7 columns (Amersham Biosciences). Minor changes included the elution from the heparin column using an increased NaCl concentration, up to 450 mM, and the use of a modified buffer for the Superdex 75 column (Amersham Biosciences). Sensitivity of the chimeric enzymes was determined by applying a peptide from the heparin column using an increased NaCl concentration, up to 450 mM, and the use of a modified buffer for the Superdex 75 column (25 mM HEPES [pH 7.0], 300 mM NaCl, 5 mM dithiothreitol). All of the enzymes were estimated to be more than 90% pure as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The final yield varied from 55 to 450 μg of protein per liter of culture. The highest yield was observed for the genotype-1a protease.

Peptide and inhibitor synthesis. The substrate peptides DDIVPC-SM-lysine were prepared by using standard solid-phase peptide synthesis methodology (3). Additional NS4A cofactor peptides were obtained from Multiple Peptide Systems (San Diego, Calif.): KKGCVATIGRIHINHHK (genotype 1a), KKGCSVIGRHLNRK (genotype 1b), and KKGCVVVGHIRLGGKK (genotype 1c), N-terminal and C-terminal lysines were added to enhance solubility. Each NS4A protease matches the sequence of the corresponding NS4A protein as obtained from infected patients (see above). Radiolabeled biotin-DDIVPC-SM-lysine was prepared from the dimer of the unlabeled peptide to label the cysteine residue from oxidation. Following the introduction of 125I (3.7 GBq/ml; Amersham Biosciences) by using the iodogen procedure (Pierce), a reduction step was performed to generate the monomer form. The radiolabeled peptide was purified by high-performance liquid chromatography on a C4 column by using a gradient of 20 to 60% acetonitrile in water. The internally quenched depsipeptide fluorogenic substrates anthranilyl-DDI
VPAbu[C(O)-O]AMY(3-NO₂)TW-OH and anthranilyl-D(d)EIVP-NVal[C(O)-O]AMY(3-NO₂)TW-OH, designed on the basis of the NS3A/5B cleavage site, was assayed in 50 mM Tris-HCl (pH 8.0) – 0.25 M sodium citrate – 0.01% K₉m. The cleavage reaction was continuously monitored at 23°C on a BMG POLARstar Galaxy fluorimeter, equipped with excitation and emission filters of 320 and 405 nm, respectively, in the presence of 0.1 to 12 μM substrate. The NS3–NS4A protein (0.5 to 3 nM) was assayed in 50 mM Tris-HCl (pH 8.0) – 0.25 M sodium citrate – 0.01% n-dodecyl-β-D-maltoside – 1 mM TCEP. The NS3 protein (5 to 50 nM) was assayed in 50 mM Tris-HCl (pH 7.5) – 30% glycerol – 1 mg of bovine serum albumin/ml – 1 mM TCEP with or without a 1,000-fold molar excess of the NS4A peptide.

The reaction was terminated by the sequential addition of 1 M morpholinoethane-sulfonic acid (pH 5.8) and 0.5 N NaOH. The substrate was separated from the products by adding the assay mixture to avidin-coated agarose beads ( Pierce), followed by a 60-min incubation at 23°C and filtration on a Millipore NAD65 plate. The amount of radiolabeled product found in the filtrate was quantitated by using a Canberry-Packard TopCount detector or an LKB Multigamma detector. Kinetic parameter calculations were performed as described above.

**RESULTS**

Characterization of the NS3–NS4A proteases of genotypes 1, 2, and 3. A comparative analysis of protease activity was performed using the NS3–NS4A full-length proteins of HCV genotypes 1a, 1b, 2a, 2b, 2a, and 3a. All NS3–NS4A proteins, when expressed in E. coli, autocleaved at the NS3/4A junction, resulting in a tight, stable heterodimeric complex that was purified via two chromatographic steps (data not shown). To facilitate comparisons between the different proteins, an internally quenched fluorogenic depsipeptide substrate and a peptide substrate, both derived from the genotype-1 NS5A/5B cleavage site, were used for all proteins. Alignment of the amino acids spanning the P6–P6' region at the NS3A/4B, NS4B/5A, and NS5A/5B junctions revealed that the NS5A/5B sequence was the most conserved among genotypes.

Characterization of the various enzymes by use of the fluorogenic substrate (Table 1) showed similar catalytic efficiencies for genotypes 1, 2, and 3, ranging from 3.1 × 10⁴ to 7.1 × 10³ M⁻¹ s⁻¹. The Km and k₉m values differed less than threefold, ranging from 1.0 to 2.6 μM and 36 to 93 min⁻¹, respectively. Kinetic parameters determined in a radiometric assay using the peptide substrate also showed similar catalytic efficiencies, ranging from 3.2 × 10³ to 6.9 × 10⁴ M⁻¹ s⁻¹. The Km and k₉m values differed less than six- and threefold, ranging from 1.9 to 12 μM and 7.2 to 23 min⁻¹, respectively. For all NS3–NS4A enzymes, however, the catalytic efficiencies of the proteases, three steps are involved in substrate hydrolysis: substrate binding, acylation, and deacylation. The acyl enzyme is formed upon attack of the active site serine on the carbonyl carbon of the substrate. Acylation is the rate-limiting step for amide substrates, while deacylation is rate-limiting for ester substrates. The similar values for k₉m with the peptide substrate also suggested similar acylation rates for all enzymes. Inhibition of the NS3–NS4A proteases of genotypes 1, 2, and 3 with BILN 2061. The backbone amides of tripeptide NS3 protease inhibitors such as BILN 2061 (Fig. 1) are believed to interact with the active site residues in the same way as do substrates. However, peptidic inhibitors derive their very high affinity for the active site in part by capitalizing on additional interactions. BILN 2061 was highly optimized for genotype-1.
BILN 2061 is most active against genotypes 1a and 1b, with $K_i$ from recombinant baculoviruses (12). The genotype-2 and -3 higher than those previously reported with proteases expressed values of 1.5 and 1.6 nM, respectively. These values are slightly determine how the af to sequence differences than is substrate binding. We wished to enzymes; thus, binding of this inhibitor might be more sensitive to sequence differences than is substrate binding. We wished to determine how the affinity for BILN 2061 was affected by the sequence differences of enzymes from various genotypes (Fig. 2A). In vitro sensitivities of the NS3–NS4A proteins to BILN 2061 were evaluated, and $K_i$ values are reported in Table 2. BILN 2061 is most active against genotypes 1a and 1b, with $K_i$ values of 1.5 and 1.6 nM, respectively. These values are slightly higher than those previously reported with proteases expressed from recombinant baculoviruses (12). The genotype-2 and -3 proteins were less sensitive to inhibition by BILN 2061, with $K_i$ values ranging from 83 to 90 nM, up to 56-fold higher than the $K_i$ obtained for genotype 1b. The inhibition data indicate that binding of BILN 2061 is more sensitive to natural variation in the NS3–NS4A protease sequence than is binding of substrate peptides.

**Role of inhibitor binding-site residues.** We reasoned that variation of amino acids close to the bound inhibitor could account for the observed differences in sensitivity to BILN 2061. Nineteen residues located within 5 Å of the inhibitor were identified (Fig. 2A) by using the crystal structure of an inhibitor-enzyme complex previously reported for an analog of BILN 2061 (Fig. 2B) (29). This analog displayed affinities similar to those of BILN 2061 for the NS3–NS4A proteins of genotypes 1, 2, and 3 (unpublished data). Sequence alignment of the residues in the inhibitor binding site revealed that 13 out of these 19 residues were conserved. There are differences at positions 78 (Val, Ser, or Ala), 79 (Asp or Gln), 80 (Gln or Gly), 123 (Arg or Thr), 132 (Ile, Val, or Leu), and 168 (Asp or Gln) (Fig. 2). To determine the degree to which the decrease in the affinity of BILN 2061 toward genotype-2 and -3 proteases was attributable to differences in these inhibitor binding-site residues, NS3–NS4A mutant enzymes were constructed. The residues in genotype 1b were replaced with the corresponding binding-site residues for genotypes 2b and 3a, to yield chimeric enzymes designated 1b/2bIBS (V78A D79E Q80G) and 1b/3aIBS (R123T V132L D168Q).

The activities of the genotype chimeras were assessed by using the peptide substrate DDIVPC-SMSYTW-OH. The $K_m$ and $k_{cat}$ values observed for both 1b/2bIBS and 1b/3aIBS were similar to those obtained with the parental 1b enzyme, although the differences in these parameters are relatively small among the various enzymes (Fig. 3A and B). However, the binding of the NS3 protease inhibitor BILN 2061 was significantly affected by the mutations. For the 1b/2bIBS mutant enzyme, a $K_i$ of 13 nM was observed, in comparison to $K_i$s of 1.6 and 83 nM for the 1b and 2b enzymes, respectively (Fig. 3C), suggesting that the four mutated residues partially account for the loss of affinity for BILN 2061. Based on examination of the crystal structure, we postulated that serine 122, located in close proximity to the inhibitor binding site and replaced by an arginine in genotype 2, might also be involved in inhibitor binding (Fig. 2B). Introduction of the S122R mutation into the genotype 1b/2bIBS mutant enzyme had no effect on the kinetic parameters (Fig. 3A and B) but resulted in a threefold decrease in affinity for BILN 2061 ($K_i$, 38 nM) when compared to that of 1b/2bIBS (Fig. 3C). Overall, our data suggest that the

| Table 2. NS3 protease inhibition with BILN 2061

<table>
<thead>
<tr>
<th>Protease</th>
<th>$K_i$ of BILN 2061 (nM) for genotype:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1a</td>
</tr>
<tr>
<td>NS3–NS4A protein</td>
<td>1.5</td>
</tr>
<tr>
<td>NS3–NS4A peptide</td>
<td>10</td>
</tr>
<tr>
<td>NS3</td>
<td>3.4</td>
</tr>
</tbody>
</table>

- $K_i$ determined as described in Materials and Methods. Data are averages from at least two separate determinations.
- $K_i$ calculated from the relationship between IC$_{50}$ and $K_i$ for competitive inhibition.

**FIG. 2.** Comparison of genotype-1a, -1b, -2b, -2ac, and -3a NS3 serine protease sequences. (A) Alignment of NS3 protease residues from genotypes 1a (NCBI accession no. AF009606), 1b, 2b, 2ac, and 3a (all obtained from HCV-infected individuals). Dots, residues in genotypes 1b, 2, and 3 that are identical to those in genotype 1a. Red letters, residues located within 5 Å of the inhibitor; those differing among genotypes are boxed. The catalytic triad residues are indicated by asterisks. (B) Structure of a macrocyclic tripeptide inhibitor bound to the active site of the NS3–NS4Aprotein complex (genotype 1b) as determined by X-ray structure analysis (29). Residues located within 5 Å of the inhibitor are colored: light blue for residues conserved among genotypes, light green for residues differing between genotypes 1 and 2 (Val78, Asp79, Gln80), red for residues differing between genotypes 1 and 3 (Arg123, Asp168), and dark blue for Val132, which is replaced with a leucine in both genotypes 2 and 3. Dark green is used to identify the active site residues of the inhibitor; those differing among genotypes 1, 2, and 3 (unpublished data). Sequence alignment of the residues in the inhibitor binding site revealed that 13 out of these 19 residues were conserved. There are differences at positions 78 (Val, Ser, or Ala), 79 (Asp or Gln), 80 (Gln or Gly), 123 (Arg or Thr), 132 (Ile, Val, or Leu), and 168 (Asp or Gln) (Fig. 2). To determine the degree to which the decrease in the affinity of BILN 2061 toward genotype-2 and -3 proteases was attributable to differences in these inhibitor binding-site residues, NS3–NS4A mutant enzymes were constructed. The residues in genotype 1b were replaced with the corresponding binding-site residues for genotypes 2b and 3a, to yield chimeric enzymes designated 1b/2bIBS (V78A D79E Q80G) and 1b/3aIBS (R123T V132L D168Q).

The activities of the genotype chimeras were assessed by using the peptide substrate DDIVPC-SMSYTW-OH. The $K_m$ and $k_{cat}$ values observed for both 1b/2bIBS and 1b/3aIBS were similar to those obtained with the parental 1b enzyme, although the differences in these parameters are relatively small among the various enzymes (Fig. 3A and B). However, the binding of the NS3 protease inhibitor BILN 2061 was significantly affected by the mutations. For the 1b/2bIBS mutant enzyme, a $K_i$ of 13 nM was observed, in comparison to $K_i$s of 1.6 and 83 nM for the 1b and 2b enzymes, respectively (Fig. 3C), suggesting that the four mutated residues partially account for the loss of affinity for BILN 2061. Based on examination of the crystal structure, we postulated that serine 122, located in close proximity to the inhibitor binding site and replaced by an arginine in genotype 2, might also be involved in inhibitor binding (Fig. 2B). Introduction of the S122R mutation into the genotype 1b/2bIBS mutant enzyme had no effect on the kinetic parameters (Fig. 3A and B) but resulted in a threefold decrease in affinity for BILN 2061 ($K_i$, 38 nM) when compared to that of 1b/2bIBS (Fig. 3C). Overall, our data suggest that the
The NS3 protease domains of genotypes 1, 2, and 3 were characterized in the presence and absence of NS4A cofactor peptides to catalytic activity and inhibitor binding. NS4A increases the protease activity of NS3 and is required to achieve optimal conformation of the NS3 protease active site (9, 33). Since the central hydrophobic domain is sufficient for cofactor activity (14), we evaluated the activity of each NS3 protease domain in the presence of this truncated NS4A, using the fluorescent depsipeptide substrate and an assay buffer containing 30% glycerol to favor complex formation. For each NS3 protease domain, specific cofactor peptides were synthesized with the sequence of the central hydrophobic peptide and inhibitor binding. NS4A increases the protease activity of NS3 as well as the NS4A cofactor to catalytic activity (9, 33). Since the central hydrophobic domain is sufficient for cofactor activity (14), we evaluated the activity of each NS3 protease domain in the presence of this truncated NS4A, using the fluorescent depsipeptide substrate and an assay buffer containing 30% glycerol to favor complex formation. For each NS3 protease domain, specific cofactor peptides were synthesized with the sequence of the central hydrophobic domain of the corresponding NS4A protein. A 1,000-fold molar excess was added relative to the protease concentration. Similar kinetic parameters were observed for the NS3 protease–NS4A peptide complexes, with at most a sevenfold difference in $k_{cat}/K_m$ (Table 3). $K_m$ values ranged from 1.6 to 11 μM, and $k_{cat}$ values ranged from 6.2 to 20 min$^{-1}$. The activities of the NS3 protease–NS4A peptide complexes and the NS3–NS4A proteins were measured under their respective optimal physicochemical conditions for enzymatic catalysis. Comparison of the catalytic efficiencies for all NS3 protease–NS4A peptide complexes, ranging from $1.7 \times 10^{-4}$ to $12 \times 10^{4} \text{M}^{-1} \text{s}^{-1}$, to the values obtained for the corresponding NS3–NS4A proteins revealed 5- to 33-fold-lower values for the complexes (Table 1). This finding might suggest the requirement of the helicase domain and/or the full-length NS4A cofactor for optimal activity of the protease, but it could be due in part to differences in assay buffers required for optimal activity of each protease form. In vitro sensitivities of the NS3 protease–NS4A peptide complexes to BILN 2061 were also evaluated, and $K_i$ values are reported in Table 2. As observed with the NS3–NS4A protein, BILN 2061 is most active against genotypes 1a ($K_i$, 10 nM) and

---

**TABLE 3. Kinetic parameters of the NS3-NS4A peptide complex and of the NS3 protease domain of genotypes 1, 2, and 3**

<table>
<thead>
<tr>
<th>Genotype</th>
<th>NS3pro-NS4Apeptide</th>
<th>NS3pro</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$K_m$ (μM)</td>
<td>$k_{cat}$ (min$^{-1}$)</td>
</tr>
<tr>
<td>1a</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>1b</td>
<td>7.1</td>
<td>20</td>
</tr>
<tr>
<td>2ac</td>
<td>5.5</td>
<td>6.2</td>
</tr>
<tr>
<td>2b</td>
<td>5.7</td>
<td>9.7</td>
</tr>
<tr>
<td>3a</td>
<td>1.6</td>
<td>12</td>
</tr>
</tbody>
</table>

---

$a$ Kinetic parameters were determined by using the depsipeptide fluorescent substrate anthraniloyl-DDI-VAQ(O)-AMN(3-NO$_2$)TW-OH, as described in Materials and Methods. Data are averages from at least two separate determinations.
**DISCUSSION**

The NS3 protease inhibitor BILN 2061 has been shown to rapidly reduce viral RNA plasma levels in patients infected with genotype-1 HCV. The drug discovery effort which led to this inhibitor was targeted toward genotype-1 virus because of the significant unmet medical need in this infected population. However, other HCV genotypes, in particular genotypes 2 and 3, also account for a large proportion of infections worldwide. In this study, we have compared the kinetic profiles of NS3 proteases from genotypes 1, 2, and 3 and their sensitivities to BILN 2061. The similarity of these kinetic profiles within each protease form studied supports the expectation that the overall conformation of the substrate binding site is conserved among the natural HCV variants, since substrate recognition for the NS3 protease relies on multiple weak interactions extended over several peptide bonds (10). Differences among genotypes in amino acids located in the substrate binding site have only a weak effect on substrate recognition and protease activity for the three enzyme forms used.

Our results are consistent with those of a previous study in which the activity of a single-chain NS4Apeptide-NS3 protease of genotypes 1a, 1b, and 3a was evaluated by using peptide substrates corresponding to the NS4A/4B, NS4B/5A, and NS5A/5B cleavage sites of genotype 1 or 3a (1). However, the similarity in genotype-1, -2, and -3 protease activities was observed with short, unnatural cleavage junction substrates. Examination of processing using in vitro-translated NS4A/4B, NS4B/5A, and NS5A/5B polyprotein fragments from genotype 1a revealed no measurable differences in protease activities for genotype-1 and -3 single-chain NS4Apeptide–NS3 proteases (1) but a reduction in activity for the genotype-2 NS3 protease–NS4Apeptide complex relative to that of genotypes 1 and 3 (32). Additional studies with polyprotein substrates are therefore required.

The in vitro inhibition studies conducted with all three protease forms showed that BILN 2061 is more active against genotypes 1a and 1b than against non-1 genotypes, although the fold increase in \( K_i \) for genotypes 2 and 3 varies with the protease form. We observed increases in \( K_i \) with the genotype-2 and -3 proteases ranging from 52- to 60-fold, 4- to 11-fold, and 5- to 12-fold for the NS3 protease–NS4Apeptide complex, and the NS3 protease, respectively, over values obtained with the genotype-1a or -1b enzymes. Such an observation was expected, since our NS3 protease inhibitor series was optimized for genotype-1 enzymes. However, the residues that are in direct contact with the inhibitor, as determined by X-ray data of an inhibitor-enzyme complex, are well conserved, predicting that this class of inhibitor would be active against all genotypes and subtypes. These differences in affinity among genotypes were observed using in vitro conditions optimized for enzymatic activity and more specifically for the genotype-1 enzymes. Comparison of the activity of inhibitors against the different genotypes in an HCV viral replication system or the surrogate HCV RNA replicon model will more accurately reflect their efficacy in patients infected with the different viral strains. Such comparisons should be carried out as soon as non-genotype-1 replication systems become available. Altogether, the observed kinetic profiles and the inhibitor sensitivity studies with the enzymes of various genotypes suggest that the interaction of BILN 2061 with NS3 is more sensitive to the naturally occurring polymorphism of the protease than are peptide substrates. This is, in part, due to the increased conformational rigidity of this class of inhibitors (29) as well as to distinct interactions, including a reduction in hydrogen bonding but additional hydrophobic interactions.

In some cases, amino acid differences distant from the binding site have been reported to affect inhibitor affinity (19), but we found that substitutions close to the inhibitor binding site explained most of the differences observed for BILN 2061. Chimeric NS3–NS4A proteins were made in which residues of the 1b protein close to the inhibitor binding site of the enzyme were substituted for their non-genotype-1 equivalents. Substitutions made for the first 1b/2b IBS chimera, a cluster of residues at amino acids 78 to 80 as well as residue 132, accounted for approximately one-half of the binding-energy difference between the genotype-1 and -2 enzymes. This is most likely due to residues 78 to 80, located on the E1–F1 loop, which is in close proximity to the quinoline moiety of the inhibitor. We also determined that residue 122, in which the serine found in genotype 1 was replaced with arginine, also plays a role in inhibitor binding. Residue 122 is close to charged residues Asp168 and Arg123, and replacement of the neutral serine by arginine could alter the hydrogen-bonding pattern in this region, thus affecting inhibitor binding, as has been discussed for...
substitutions at position 168 (28) (see also below). Additional mutagenesis studies will be required to identify other residue differences which have an impact on inhibitor binding.

The genotype-3a protein and the 1b/3a<sup>NS3</sup> chimeric protein were found to have similar sensitivities to BILN 2061. Furthermore, the genotype-3 residue Glu168 was identified as the major determinant for the loss of affinity of this inhibitor for the genotype-3a protease. This observation is consistent with the crystal structure of an analog of BILN 2061 bound to the NS3 protease–NS4A<sup>peptide</sup> complex, which revealed that the P2 group of the inhibitor facilitated the formation of a salt bridge between Arg155 and Asp168 (29). This could explain how mutation of Asp168 would have a significant effect on inhibitor binding even though this residue is not in direct contact with the inhibitor. The 1b/3a<sup>NS3</sup> chimera in which both amino acids 123 and 168 were mutated to polar but neutral threonine and glutamine had a slightly higher affinity for the inhibitor than did the D168Q enzyme. Mutation of both residues together preserves the net charge and may result in a less significant change in the conformation or solvation of Arg155 and, consequently, in a less significant change in the binding of BILN 2061. Amino acid 168 was previously identified in a resistance study using an acyclic analog of BILN 2061 (28). Interestingly, the substitutions D168V and D168Y found in this study had a larger effect on BILN 2061 binding than the substitution with glutamine (data not shown). An earlier study comparing genotype-1b and -3a proteases had also evaluated the contribution of residues 123 and 168 to the binding of less-optimized hexapeptide-like inhibitors (1). The residue at position 123 alone quantitatively accounted for the differences in sensitivities between genotype-1 and -3a enzymes, while substitution of residue 168 alone had no effect on inhibitor binding in this case. The latter result reflects the differences between the interactions of these two classes of inhibitors with the protease active site.

The residue at position 132 is also different in different genotypes and subtypes, but substitutions are conservative. Residue 132 is a member of the S1–S3 pocket and has been suggested to interact with the aliphatic macrocycle ring of the inhibitor (29). Since genotype-1a and -1b enzymes have similar affinities for BILN 2061, we believe that these conservative substitutions at position 132 are likely to have a modest role in the binding of BILN 2061.

Administration of 25 to 500 mg of BILN 2061 twice daily to genotype-1 HCV-infected patients for 2 days resulted in a 2- to 3-log<sub>10</sub>-unit reduction in HCV RNA plasma levels for all patients treated [Hinrichsen et al., Hepatology 36(Suppl. 1):297A, 2002]. The low-nanomolar <i>K<sub>i</sub></i> values reported here suggest that BILN 2061 should be effective in the treatment of patients with genotype-2 and -3 infections. In fact, a recently reported trial in which 500 mg of BILN 2061 was administered twice daily for 2 days to patients infected with non-genotype-1 viruses indicated a significant reduction in HCV RNA plasma levels for the majority of patients, although the response was not as robust as that observed for genotype-1 infections (M. Reiser, H. Hinrichsen, Y. Benhamou, R. Sentjens, H. Wede-}

meyer, L. Calleja, X. Forns, J. Croenlein, C. Yong, G. Nehmiz, and G. Steinmann, abstract from the 54th Ann. Meet. Am. Assoc. Study Liver Dis., 2003, Hepatology 38(Suppl. 1):221A, 2003; also unpublished data). Interestingly, the NS3 proteases of genotypes 2 and 3 used in this study were derived from patients exhibiting a broad range of viral-load reductions upon BILN 2061 administration. We found that the response observed for the source patient was not dependent on the in vitro sensitivity to BILN 2061. The less-robust in vivo efficacy of BILN 2061 for patients with genotype-2 and -3 infections may depend not only on the reduced in vitro inhibitory activity but also on differences in the replication kinetics for different genotypes and patient-to-patient differences in viral replication and compound pharmacokinetic properties. In particular, variation in viral kinetics has been identified as a major determinant in disease progression (7). The use of a specific anti-HCV agent such as BILN 2061 should allow a better estimation of the viral-replication kinetics in infected patients than those obtained with the less-specific treatment of interferon plus ribavirin.

**ACKNOWLEDGMENTS**

We thank Dominik Wernic for NS4A peptide and substrate synthesis; Vida Gorys for BILN 2061 synthesis; Mireille Cartier for sequence alignments; Lynn Amon for molecular modeling; Nathalie Goudreau for providing Fig. 2B; Amélie Fradot-Turcotte, Yelena Markovich, and Joseph Walton for valuable technical assistance; and Montse Linánez-Brunet for critical reading of the manuscript. Finally, we are grateful to Michael G. Cordin for his continuous support.

**REFERENCES**